265 related articles for article (PubMed ID: 27767328)
1. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.
Martinez FJ; Vestbo J; Anderson JA; Brook RD; Celli BR; Cowans NJ; Crim C; Dransfield M; Kilbride S; Yates J; Newby DE; Niewoehner D; Calverley PM;
Am J Respir Crit Care Med; 2017 Apr; 195(7):881-888. PubMed ID: 27767328
[TBL] [Abstract][Full Text] [Related]
2. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
[TBL] [Abstract][Full Text] [Related]
3. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
5. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
Crim C; Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Lettis S; Calverley PM
Ann Am Thorac Soc; 2015 Jan; 12(1):27-34. PubMed ID: 25490706
[TBL] [Abstract][Full Text] [Related]
6. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
7. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
8. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
9. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R;
Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
[TBL] [Abstract][Full Text] [Related]
10. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
Covelli H; Pek B; Schenkenberger I; Scott-Wilson C; Emmett A; Crim C
Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
15. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis.
Hinds DR; DiSantostefano RL; Le HV; Pascoe S
BMJ Open; 2016 Jun; 6(6):e010099. PubMed ID: 27251682
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
18. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
Vestbo J; Leather D; Diar Bakerly N; New J; Gibson JM; McCorkindale S; Collier S; Crawford J; Frith L; Harvey C; Svedsater H; Woodcock A;
N Engl J Med; 2016 Sep; 375(13):1253-60. PubMed ID: 27593504
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
